Hamid Bahadori, MD

Articles by Hamid Bahadori, MD

Irinotecan in the Management of Patients With Pancreatic Cancer

ByMark R. Green, MD,Melinda Harper, RN,Ahmad R. Safa, MD, PhD,Carol A. Sherman, MD,Chaudry M. Mushtaq, MD,Hamid Bahadori, MD,Frank J. Brescia, MD,Caio Max S. Rocha Lima, MD

December 3rd 2000

Synergy with no overlapping toxicities has been demonstrated for the combination of irinotecan ( Camptosar, CPT-11) and gemcitabine (Gemzar) in vitro. Results of a single-institution phase I study in which patients with

Latest Updated Articles

Irinotecan in the Management of Patients With Pancreatic Cancer
Published: December 3rd 2000 | Updated:

Hamid Bahadori, MD

Articles by Hamid Bahadori, MD

Irinotecan in the Management of Patients With Pancreatic Cancer

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

FDA Approves Revumenib in R/R NPM1-Mutant AML

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology